0

Gadolinium (III) Oxide Nanoparticles Coated With Folic Acid-Functionalized poly(β-cyclodextrin-co-pentetic Acid) as a Biocompatible Targeted Nano-Contrast Agent for Cancer Diagnostic: In Vitro and in Vivo Studies

Tohid Mortezazadeh, Elham Gholibegloo, Nader Riyahi Alam, Sadegh Dehghani, Soheila Haghgoo, Hossein Ghanaati, Mehdi Khoobi

MAGMA. 2019 Aug;32(4):487-500.

PMID: 30730021

Abstract:

Objectives:
In this study, a novel targeted MRI contrast agent was developed by coating gadolinium oxide nanoparticles (Gd2O3 NPs) with β-cyclodextrin (CD)-based polyester and targeted by folic acid (FA).
Materials and methods:
The developed Gd2O3@PCD-FA MRI contrast agent was characterized and evaluated in relaxivity, in vitro cell targeting, cell toxicity, blood compatibility and in vivo tumor MR contrast enhancement.
Results:
In vitro cytotoxicity and hemolysis assays revealed that Gd2O3@PCD-FA NPs have no significant cytotoxicity after 24 and 48 h against normal human breast cell line (MCF-10A) at concentration of up to 50 µg Gd+3/mL and have high blood compatibility at concentration of up to 500 µg Gd+3/mL. In vitro MR imaging experiments showed that Gd2O3@PCD-FA NPs enable targeted contrast T1- and T2-weighted MR imaging of M109 as overexpressing folate receptor cells. Besides, the in vivo analysis indicated that the maximum contrast-to-noise ratio (CNR) of tumor in mice increased after injection of Gd2O3@PCD-FA up to 5.89 ± 1.3 within 1 h under T1-weighted imaging mode and reduced to 1.45 ± 0.44 after 12 h. While CNR increased up to maximum value of 1.98 ± 0.28 after injection of Gd2O3@PCD within 6 h and reduced to 1.12 ± 0.13 within 12 h.
Conclusion:
The results indicate the potential of Gd2O3@PCD-FA to serve as a novel targeted nano-contrast agent in MRI.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP12064629 Gadolinium(III) oxide Gadolinium(III) oxide 12064-62-9 Price
AP67436-A Pentetic acid Pentetic acid 67-43-6 Price
qrcode